An investigation for investors in Myriad Genetics, Inc. (NASDAQ: MYGN) shares over potential securities laws violations by Myriad Genetics, Inc. was announced and NASDAQ: MYGN stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 03/21/2018 -- An investigation was announced for investors in NASDAQ: MYGN shares over potential securities laws violations by Myriad Genetics, Inc. in connection with certain financial statements.
Investors who purchased shares of Myriad Genetics, Inc. (NASDAQ: MYGN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether certain statements by Myriad Genetics, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Salt Lake City, UT based Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. Myriad Genetics, Inc. reported that its Total Revenue rose from $753.8 million for the 12 months period that ended on June 30, 2016 to $771.4 million for the 12 months period that ended on June 30, 2017 and that its Net Income declined over those respective time periods declined from $125.3 million to $21.8 million.
On March 12, 2018, Myriad Genetics, Inc. disclosed that it had received a subpoena from the Department of Health and Human Services, Office of Inspector General, in connection with an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid. The subpoena requested that the Company produce documents relating primarily to the Company's billing to government-funded healthcare programs for the Company's hereditary cancer testing.
Shares of Myriad Genetics, Inc. (NASDAQ: MYGN) declined from $33.73 per share on March 12, 2018 to as low as $28.51 per share on March 13, 2018.
On March 20, 2018, NASDAQ:MYGN shares closed at $29.30 per share.
Those who purchased shares of Myriad Genetics, Inc. (NASDAQ: MYGN) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com